Retagliptin
Retagliptin (SP2086) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin can be used for type 2 diabetes mellitus (T2DM) research[1].
Product Specifications
CAS Number
1174122-54-3
Product Name Alternative
SP2086
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Dipeptidyl Peptidase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/retagliptin.html
Purity
99.70
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=C2CN(C(C[C@H](N)CC3=CC(F)=C(F)C=C3F)=O)CCN2C(C(F)(F)F)=N1)OC
Molecular Formula
C19H18F6N4O3
Molecular Weight
464.36
Precautions
H302, H315, H319, H335
References & Citations
[1]Avivit Cahn, et al. An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opin Emerg Drugs. 2016 Dec;21 (4) :409-419.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
DPP-4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
GSK3 Alpha + Beta Rabbit Polyclonal Antibody (Cy3)
Lentiviral human C19orf47 shRNA (UAS) - Lentiviral human C19orf47 shRNA (UAS, iRFP) plasmid
